US 12,252,541 B2
Anti-BCMA antibody and use thereof
Kyungjin Park, Gyeonggi-Do (KR); Hyejin Chung, Gyeonggi-do (KR); Kyeongsu Park, Gyeonggi-do (KR); Yangsoon Lee, Gyeonggi-do (KR); Mikyung Chang, Gyeonggi-do (KR); Jaehyoung Jeon, Gyeonggi-do (KR); Youngkwang Kim, Gyeonggi-do (KR); Junhyun Jeong, Gyeonggi-do (KR); Jiseon Yoo, Gyeonggi-do (KR); Yeunju Kim, Gyeonggi-do (KR); Donghoon Yeom, Gyeonggi-do (KR); Eunjung Kim, Gyeonggi-do (KR); Bora Lee, Gyeonggi-do (KR); and Jinwon Jung, Gyeonggi-do (KR)
Assigned to ABL BIO INC., Gyeonggi-do (KR)
Appl. No. 17/053,256
Filed by ABL BIO INC., Gyeonggi-do (KR)
PCT Filed Jun. 26, 2019, PCT No. PCT/KR2019/007727
§ 371(c)(1), (2) Date Nov. 5, 2020,
PCT Pub. No. WO2020/004934, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 10-2018-0073320 (KR), filed on Jun. 26, 2018.
Prior Publication US 2021/0284749 A1, Sep. 16, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. An antibody or an antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA), wherein said antibody or antigen-binding fragment comprises:
(a) a complementarity-determining region-H1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 27,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 35,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 56,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 75;
(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 76;
(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 58,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77;
(d) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 30,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 49,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 59,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 78;
(e) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 120,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 76;
(f) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 76;
(g) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 122;
(h) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123;
(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 120,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 122;
(j) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 120,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123;
(k) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 122;
(l) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123;
(m) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 124,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77,
(n) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 125,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77;
(o) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 126,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77;
(p) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 127,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and
a CDR-L3 comprising the amino acid sequence SEQ ID NO: 77; and
(q) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,
a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,
a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,
a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 128,
a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and
a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77.